Roivant Sciences Reports Q3 2025 Earnings: Strong Pipeline Progress, Financial Position Amidst Litigation and Competitive Landscape Concerns.

Roivant Sciences reported a total non-GAAP net loss of $167 million for Q3 2025, with $4.5 billion in consolidated cash. The company achieved positive phase 2 results for Brepo in cutaneous sarcoidosis, with a significant placebo-adjusted improvement of 21.6 points. Roivant has fully enrolled its phase 2b study for DCRA and phase 2 study for PHLD, indicating strong progress in its pipeline. The company maintains a robust pipeline with multiple registrational programs and is on track for multiple pivotal study readouts and potential commercial launches.